NEWS
2025.07.01
Presentation at the Nucleic Acids Therapeutics Society of Japan.
We made a presentation at the 10th Annual Meeting of NatsJ (Nucleic Acids Therapeutics Society of Japan).
2024.08.01
Notice of establishment of Tokyo Office.
Due to business expansion, we have opened a new office in Tokyo.
2024.05.07
Notice of Third Party Allotment of New Shares.
aceRNA Technologies Secures 960 million JPY Series B to develop targeted mRNA therapeutics.
Click here for details.
2024.02.14
We and Pfizer entered into an agreement to collaborate on RNA switch technology.
aceRNA Technology and Pfizer entered into an agreement to collaborate on RNA switch technology. In the collaboration, we aim to engineer RNA switch for potential targeted mRNA medicines.
2023.09.21
It was featured in Nikkei Biotech.
An article about our company was published in Nikkei Biotech. Related link click here(in Japanese).
2022.09.28
Selected as a finalist of “Japan Innovation Bloom GRANT CALL 2022”.
Related link click here(in Japanese).
2022.05.26
Notice of Change in President & CEO
As of May 26th, Teruo Susumu has resigned from his position as President and CEO at aceRNA Technologies. Fumihiro Sugawa will serve as the new President and CEO. We will continue to develop “smart gene therapy” (mRNA-based and virus-base) that enables control of therapeutic transgene expression in cell-type and -state specific manner.
2021.12.20
We and Nitto Denko entered into an agreement to jointly develop Switch mRNA Therapy.
We are pleased to announce that we have signed an agreement to jointly develop Switch mRNA Therapy.
2021.12.20
Close of Series B funding.
aceRNA Technologies has raised funds from Nitto Denko and Mitsubishi UFJ Capital. aceRNA will use this capital to develop “smart gene therapy” (mRNA-based and virus-base) that enables
control of therapeutic transgene expression in cell-type and -state specific manner.
2021.11.05
We have been selected for the Startup City Acceleration Program promoted by the Japan External Trade Organization (JETRO).
Related link click here(in Japanese).
2021.10.09
We received Senju Pharmaceutical Award at Medtech Grand Prix KOBE2021 organized by Leave a Nest Co., Ltd.
Related link click here(in Japanese).
2021.10.05
We won 2nd Prize in Boehringer Ingelheim Innovation Prize 2021.
Related link click here(in Japanese).
2021.04.05
An article about our collaborative research with JCR Pharma Co., Ltd. was published in Nikkei Biotech.
An article about the joint research agreement was published in Nikkei Biotech on March 30th.
Related link click here(in Japanese).
2021.03.30
We have entered into a joint research agreement with JCR Pharmaceuticals.
We are pleased to announce that we have signed a joint research agreement with JCR Pharmaceuticals for the purpose of modifying cell functions by controlling gene expression using our RNA Switch® technology.
2020.09.15
Featured on Startup Guide Japan.
Our company was featured in the Japanese edition of Startup Guide, which introduces startup companies around the world.
2020.09.08
We have been selected for the FY2020 Strategic Basic Technology Advancement Support Program.
Related link click here(in Japanese).
2019.10.31
Close of Series A funding.
aceRNA Technologies has raised funds from Kyoto University Innovation Capital, SMBC Venture Capital, and several individual investors. aceRNA will use this capital to explore regenerative medicine and drug discovery targets using our technology.
2019.07.30
We have been selected for the FY2018 supplementary manufacturing subsidy.
Related link click here(in Japanese).
2018.12.19
We have been selected for “Industry-Academia-Public Forest” promotion project in 2018 by KYOTO Industrial Support Organization 21.
KYOTO Industrial Support Organization 21, a Public Interest Incorporated Foundation, selected our project as “Industry-Academia-Public Forest” promotion project in 2018.
2018.11.08
Close of seed round funding.
aceRNA Technologies, which is based on the RNA switch technology invented by Professor Hirohide Saitoh of the Kyoto University iPS Cell Research Institute, has raised capital from Kyoto University Innovation Capital. We are pleased to announce that we will use the funds raised to promote research and development for the sale of RNA switch research reagents, and to further grow our business.
2018.09.27
We have been selected for the Mitsubishi UFJ Technology Development Foundation's "1st Research and Development Grant for FY2018."
Related link click here(in Japanese).